HDL and glucose metabolism: Current evidence and therapeutic potential

Frontiers in Pharmacology

Volumn 6, Issue OCT, 2015, Pages

  Siebel, Andrew L ^a   Heywood, Sarah Elizabeth ^a   Kingwell, Bronwyn A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Apolipoprotein A I; Cholesterol efflux; Glucose metabolism; Glucose uptake; HDL; Insulin secretion; Insulin sensitivity

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ALZHEIMER DISEASE; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEART PROTECTION; INSULIN RELEASE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPID STORAGE; METABOLIC REGULATION; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; SHORT SURVEY; SKELETAL MUSCLE;

EID: 84947213758     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00258     Document Type: Short Survey

References (81)

1. Abderrahmani, A., Niederhauser, G., Favre, D., Abdelli, S., Ferdaoussi, M., Yang, J. Y., et al. (2007). Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50, 1304-1314. doi: 10.1007/s00125-007-0642-z
2. Barter, P. J., Rye, K. A., Tardif, J. C., Waters, D. D., Boekholdt, S. M., Breazna, A., et al. (2011). Effect of torcetrapib on glucose, insulin, and hemoglobin a1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial. Circulation 124, 555-562. doi: 10.1161/CIRCULATIONAHA.111.018259
3. Briand, F., Prunet-Marcassus, B., Thieblemont, Q., Costard, C., Muzotte, E., Sordello, S., et al. (2014). Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters. Atherosclerosis 233, 359-362. doi: 10.1016/j.atherosclerosis.2014.01.028
4. Brulhart-Meynet, M. C., Braunersreuther, V., Brinck, J., Montecucco, F., Prost, J. C., Thomas, A., et al. (2015). Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury. PLoS ONE 10:e0119664. doi: 10.1371/journal.pone.0119664
5. Brunham, L. R., Kruit, J. K., Pape, T. D., Timmins, J. M., Reuwer, A. Q., Vasanji, Z., et al. (2007). Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13, 340-347. doi: 10.1038/nm1546
6. Calabresi, L., Rossoni, G., Gomaraschi, M., Sisto, F., Berti, F., and Franceschini, G. (2003). High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ. Res. 92, 330-337. doi: 10.1161/01.RES.0000054201.60308.1A
7. Cantrell Stanford, J., Morris, A. J., Sunkara, M., Popa, G. J., Larson, K. L., and Ozcan, S. (2012). Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 287, 13457-13464. doi: 10.1074/jbc.M111.268185
8. Carey, A. L., Siebel, A. L., Reddy-Luthmoodoo, M., Natoli, A. K., D'souza, W., Meikle, P. J., et al. (2013). Skeletal muscle insulin resistance associated with cholesterol-induced activation of macrophages is prevented by high density lipoprotein. PLoS ONE 8:e56601. doi: 10.1371/journal.pone.0056601
9. Carvalho, L. S., Cintra, R. M., Moura, F. A., Martins, N. V., Quinaglia, E. S. J. C., Coelho, O. R., et al. (2012). High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis 220, 231-236. doi: 10.1016/j.atherosclerosis.2011.09.044
10. Carvalho, L. S., Martins, N. V., Moura, F. A., Cintra, R. M., Almeida, O. L., Quinaglia e Silva, J. C., et al. (2013). High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: a study by euglycemic hyperinsulinemic clamp. J. Clin. Lipidol. 7, 24-28. doi: 10.1016/j.jacl.2012.10.003
11. Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., and Beach, T. (2006). Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155-163. doi: 10.1179/016164106X98035
12. Cobelli, C., Dalla Man, C., Toffolo, G., Basu, R., Vella, A., and Rizza, R. (2014). The oral minimal model method. Diabetes Metab. Res. Rev. 63, 1203-1213. doi: 10.2337/db13-1198
13. Cochran, B. J., Bisoendial, R. J., Hou, L., Glaros, E. N., Rossy, J., Thomas, S. R., et al. (2014). Apolipoprotein A-I increases insulin secretion and production from pancreatic beta-cells via a G-protein-cAMP-PKA-FoxO1-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 34, 2261-2267. doi: 10.1161/ATVBAHA.114.304131
14. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. doi: 10.1126/science.8346443
15. Dalla-Riva, J., Stenkula, K. G., Petrlova, J., and Lagerstedt, J. O. (2013). Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle. J. Lipid Res. 54, 1275-1282. doi: 10.1194/jlr.M032904
16. Di Marco, L. Y., Venneri, A., Farkas, E., Evans, P. C., Marzo, A., and Frangi, A. F. (2015). Vascular dysfunction in the pathogenesis of Alzheimer's disease-a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol. Dis. doi: 10.1016/j.nbd.2015.08.014 [Epub ahead of print].
17. Drew, B. G., Duffy, S. J., Formosa, M. F., Natoli, A. K., Henstridge, D. C., Penfold, S. A., et al. (2009). High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119, 2103-2111. doi: 10.1161/CIRCULATIONAHA.108.843219
18. Drew, B. G., Fidge, N. H., Gallon-Beaumier, G., Kemp, B. E., and Kingwell, B. A. (2004). High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 101, 6999-7004. doi: 10.1073/pnas.0306266101
19. Drew, B. G., Rye, K. A., Duffy, S. J., Barter, P., and Kingwell, B. A. (2012). The emerging role of HDL in glucose metabolism. Nat. Rev. Endocrinol. 8, 237-245. doi: 10.1038/nrendo.2011.235
20. Drexel, H., Aczel, S., Marte, T., Benzer, W., Langer, P., Moll, W., et al. (2005). Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28, 101-107. doi: 10.2337/diacare.28.1.101
21. Fagan, A. M., Holtzman, D. M., Munson, G., Mathur, T., Schneider, D., Chang, L. K., et al. (1999). Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J. Biol. Chem. 274, 30001-30007. doi: 10.1074/jbc.274.42.30001
22. Ford, E. S., Giles, W. H., and Dietz, W. H. (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359. doi: 10.1001/jama.287.3.356
23. Fryirs, M., Barter, P. J., and Rye, K. A. (2009). Cholesterol metabolism and pancreatic beta-cell function. Curr. Opin. Lipidol. 20, 159-164. doi: 10.1097/MOL.0b013e32832ac180
24. Gatti, A., Maranghi, M., Bacci, S., Carallo, C., Gnasso, A., Mandosi, E., et al. (2009). Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 32, 1550-1552. doi: 10.2337/dc09-0256
25. Haase, C. L., Tybjaerg-Hansen, A., Nordestgaard, B. G., and Frikke-Schmidt, R. (2015). High-density lipoprotein cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes 64, 3328-3333. doi: 10.2337/db14-1603
26. Haffner, S. M., Stern, M. P., Hazuda, H. P., Mitchell, B. D., and Patterson, J. K. (1990). Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263, 2893-2898. doi: 10.1001/jama.1990.03440210043030
27. Han, R., Lai, R., Ding, Q., Wang, Z., Luo, X., Zhang, Y., et al. (2007). Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50, 1960-1968. doi: 10.1007/s00125-007-0752-7
28. Hanyu, H., Sato, T., Hirao, K., Kanetaka, H., Iwamoto, T., and Koizumi, K. (2010). The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer's disease: a longitudinal SPECT study. J. Neurol. Sci. 290, 96-101. doi: 10.1016/j.jns.2009.10.022
29. Hao, M., Head, W. S., Gunawardana, S. C., Hasty, A. H., and Piston, D. W. (2007). Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes Metab. Res. Rev. 56, 2328-2338. doi: 10.2337/db07-0056
30. Herholz, K. (2010). Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert. Rev. Neurother. 10, 1667-1673. doi: 10.1586/ern.10.136
31. Herzog, C., Schmitz, M., Levkau, B., Herrgott, I., Mersmann, J., Larmann, J., et al. (2010). Intravenous sphingosylphosphorylcholine protects ischemic and postischemic myocardial tissue in a mouse model of myocardial ischemia/reperfusion injury. Mediators Inflamm. 2010, 425191. doi: 10.1155/2010/425191
32. Heywood, S. E., Henstridge, D. C., Carey, A. L., Delbridge, L. M., Kingwell, B. A., and Siebel, A. L. (2014). "High-density lipoprotein modulates cardiomyocyte glucose metabolism via an insulin-independent mechanism involving Akt". in American Heart Association Conference, Chicago, IL.
33. Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature 444, 860-867. doi: 10.1038/nature05485
34. Icks, A., Claessen, H., Kirchberger, I., Heier, M., Peters, A., Trentinaglia, I., et al. (2014). Mortality after first myocardial infarction in diabetic and non-diabetic people between 1985 and 2009. The MONICA/KORA registry. Eur. J. Epidemiol. 29, 899-909. doi: 10.1007/s10654-014-9964-6
35. Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., et al. (2010). The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 6, 221-229. doi: 10.1016/j.jalz.2010.03.003
36. Jagust, W. J., Eberling, J. L., Reed, B. R., Mathis, C. A., and Budinger, T. F. (1997). Clinical studies of cerebral blood flow in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826, 254-262. doi: 10.1111/j.1749-6632.1997.tb48477.x
37. Johnson, K. A., Jones, K., Holman, B. L., Becker, J. A., Spiers, P. A., Satlin, A., et al. (1998). Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50, 1563-1571. doi: 10.1212/WNL.50.6.1563
38. Kang, M. H., Zhang, L. H., Wijesekara, N., De Haan, W., Butland, S., Bhattacharjee, A., et al. (2013). Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler. Thromb. Vasc. Biol. 33, 2724-2732. doi: 10.1161/ATVBAHA.113.302004
39. Kawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., and Ueki, A. (1995). Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin. Chim. Acta 239, 209-211. doi: 10.1016/0009-8981(95)06115-T
40. Khera, A. V., Cuchel, M., De La Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., et al. (2011). Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135. doi: 10.1056/NEJMoa1001689
41. Kim, S. M., Kim, M. J., Rhee, H. Y., Ryu, C. W., Kim, E. J., Petersen, E. T., et al. (2013). Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele. Neuroradiology 55, 25-34. doi: 10.1007/s00234-012-1077-x
42. Kingwell, B. A., and Chapman, M. J. (2013). Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation 128, 1112-1121. doi: 10.1161/CIRCULATIONAHA.113.002683
43. Kingwell, B. A., Chapman, M. J., Kontush, A., and Miller, N. E. (2014). HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 13, 445-464. doi: 10.1038/nrd4279
44. Klop, B., Elte, J. W., and Cabezas, M. C. (2013). Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 5, 1218-1240. doi: 10.3390/nu5041218
45. Koch, S., Donarski, N., Goetze, K., Kreckel, M., Stuerenburg, H. J., Buhmann, C., et al. (2001). Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42, 1143-1151.
46. Kruit, J. K., Wijesekara, N., Westwell-Roper, C., Vanmierlo, T., De Haan, W., Bhattacharjee, A., et al. (2012). Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function. Diabetes Metab. Res. Rev. 61, 659-664. doi: 10.2337/db11-1341
47. Kuriyama, M., Takahashi, K., Yamano, T., Hokezu, Y., Togo, S., Osame, M., et al. (1994). Low levels of serum apolipoprotein A I and A II in senile dementia. Jpn. J. Psychiatry Neurol. 48, 589-593.
48. LaDu, M. J., Gilligan, S. M., Lukens, J. R., Cabana, V. G., Reardon, C. A., Van Eldik, L. J., et al. (1998). Nascent astrocyte particles differ from lipoproteins in CSF. J. Neurochem. 70, 2070-2081. doi: 10.1046/j.1471-4159.1998.70052070.x
49. Lefterov, I., Fitz, N. F., Cronican, A. A., Fogg, A., Lefterov, P., Kodali, R., et al. (2010). Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J. Biol. Chem. 285, 36945-36957. doi: 10.1074/jbc.M110.127738
50. Lehti, M., Donelan, E., Abplanalp, W., Al-Massadi, O., Habegger, K. M., Weber, J., et al. (2013). High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation 128, 2364-2371. doi: 10.1161/CIRCULATIONAHA.113.001551
51. Lehtinen, M. K., Bjornsson, C. S., Dymecki, S. M., Gilbertson, R. J., Holtzman, D. M., and Monuki, E. S. (2013). The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. J. Neurosci. 33, 17553-17559. doi: 10.1523/JNEUROSCI.3258-13.2013
52. Masoud, W. G., Ussher, J. R., Wang, W., Jaswal, J. S., Wagg, C. S., Dyck, J. R., et al. (2014). Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc. Res. 101, 30-38. doi: 10.1093/cvr/cvt216
53. McGrath, K. C., Li, X. H., Whitworth, P. T., Kasz, R., Tan, J. T., Mclennan, S. V., et al. (2014). High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation. J. Lipid Res. 55, 421-430. doi: 10.1194/jlr.M043281
54. Merched, A., Xia, Y., Visvikis, S., Serot, J. M., and Siest, G. (2000). Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 21, 27-30. doi: 10.1016/S0197-4580(99)00103-7
55. Mineo, C., Yuhanna, I. S., Quon, M. J., and Shaul, P. W. (2003). High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278, 9142-9149. doi: 10.1074/jbc.M211394200
56. Navab, M., Reddy, S. T., Van Lenten, B. J., and Fogelman, A. M. (2011). HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8, 222-232. doi: 10.1038/nrcardio.2010.222
57. Nicolakakis, N., and Hamel, E. (2011). Neurovascular function in Alzheimer's disease patients and experimental models. J. Cereb. Blood Flow Metab. 31, 1354-1370. doi: 10.1038/jcbfm.2011.43
58. Paula-Lima, A. C., Tricerri, M. A., Brito-Moreira, J., Bomfim, T. R., Oliveira, F. F., Magdesian, M. H., et al. (2009). Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int. J. Biochem. Cell Biol. 41, 1361-1370. doi: 10.1016/j.biocel.2008.12.003
59. Petremand, J., Bulat, N., Butty, A. C., Poussin, C., Rutti, S., Au, K., et al. (2009). Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta-cells. Mol. Endocrinol. 23, 1572-1586. doi: 10.1210/me.2008-0448
60. Pitas, R. E., Boyles, J. K., Lee, S. H., Hui, D., and Weisgraber, K. H. (1987). Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J. Biol. Chem. 262, 14352-14360.
61. Riwanto, M., and Landmesser, U. (2013). High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid Res. 54, 3227-3243. doi: 10.1194/jlr.R037762
62. Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., et al. (2014). HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371, 2383-2393. doi: 10.1056/NEJMoa1409065
63. Roher, A. E., Maarouf, C. L., Sue, L. I., Hu, Y., Wilson, J., and Beach, T. G. (2009). Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 14, 493-501. doi: 10.3109/13547500903108423
64. Rutti, S., Ehses, J. A., Sibler, R. A., Prazak, R., Rohrer, L., Georgopoulos, S., et al. (2009). Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150, 4521-4530. doi: 10.1210/en.2009-0252
65. Saleheen, D., Scott, R., Javad, S., Zhao, W., Rodrigues, A., Picataggi, A., et al. (2015). Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 3, 507-513. doi: 10.1016/S2213-8587(15)00126-6
66. Shin, J., Lee, S. Y., Kim, S. J., Kim, S. H., Cho, S. J., and Kim, Y. B. (2010). Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 52, 488-496. doi: 10.1016/j.neuroimage.2010.04.013
67. Siebel, A. L., Natoli, A. K., Yap, F. Y., Carey, A. L., Reddy-Luthmoodoo, M., Sviridov, D., et al. (2013). Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ. Res. 113, 167-175. doi: 10.1161/CIRCRESAHA.113.300689
68. Stenkula, K. G., Lindahl, M., Petrlova, J., Dalla-Riva, J., Goransson, O., Cushman, S. W., et al. (2014). Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice. Diabetologia 57, 797-800. doi: 10.1007/s00125-014-3162-7
69. Stukas, S., Robert, J., Lee, M., Kulic, I., Carr, M., Tourigny, K., et al. (2014a). Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J. Am. Heart Assoc. 3, e001156. doi: 10.1161/JAHA.114.001156
70. Stukas, S., Robert, J., and Wellington, C. L. (2014b). High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. Cell Metab. 19, 574-591. doi: 10.1016/j.cmet.2014.01.003
71. Sturek, J. M., Castle, J. D., Trace, A. P., Page, L. C., Castle, A. M., Evans-Molina, C., et al. (2010). An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J. Clin. Invest. 120, 2575-2589. doi: 10.1172/JCI41280
72. Tao, R., Hoover, H. E., Honbo, N., Kalinowski, M., Alano, C. C., Karliner, J. S., et al. (2010). High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am. J. Physiol. Heart Circ. Physiol. 298, H1022-H1028. doi: 10.1152/ajpheart.00902.2009
73. Theilmeier, G., Schmidt, C., Herrmann, J., Keul, P., Schafers, M., Herrgott, I., et al. (2006). High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114, 1403-1409. doi: 10.1161/CIRCULATIONAHA.105.607135
74. Ussher, J. R., Wang, W., Gandhi, M., Keung, W., Samokhvalov, V., Oka, T., et al. (2012). Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc. Res. 94, 359-369. doi: 10.1093/cvr/cvs129
75. Verfaillie, S. C., Adriaanse, S. M., Binnewijzend, M. A., Benedictus, M. R., Ossenkoppele, R., Wattjes, M. P., et al. (2015). Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin? Eur. Radiol. 25, 3050-3059. doi: 10.1007/s00330-015-3696-1
76. Vollenweider, P., Von Eckardstein, A., and Widmann, C. (2015). HDLs, diabetes, and metabolic syndrome. Handb. Exp. Pharmacol. 224, 405-421. doi: 10.1007/978-3-319-09665-0_12
77. von Eckardstein, A., and Widmann, C. (2014). High-density lipoprotein, beta cells, and diabetes. Cardiovasc. Res. 103, 384-394. doi: 10.1093/cvr/cvu143
78. Waldman, B., Jenkins, A. J., Davis, T. M., Taskinen, M. R., Scott, R., O'connell, R. L., et al. (2014). HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care 37, 2351-2358. doi: 10.2337/dc13-2738
79. Wijesekara, N., Zhang, L. H., Kang, M. H., Abraham, T., Bhattacharjee, A., Warnock, G. L., et al. (2012). miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes Metab. Res. Rev. 61, 653-658. doi: 10.2337/db11-0944
80. Zhang, Q., Zhang, Y., Feng, H., Guo, R., Jin, L., Wan, R., et al. (2011). High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS ONE 6:e23556. doi: 10.1371/journal.pone.0023556
81. Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723-738. doi: 10.1038/nrn3114